Investing in a ground breaking peanut allergy therapy

A local biotechnology firm will bring peanut allergy sufferers around the world one step closer to an innovative new treatment that could save lives.

The Victorian Government’s $12 million investment through Breakthrough Victoria into Aravax is a part of a $66 million funding round to develop a novel peanut allergy treatment.

Aravax is a clinical stage biotechnology company focused on revolutionising food allergy treatment through its product, PVX108. The immunotherapy uses synthetic peptides to mimic key parts of peanut proteins with the potential to retrain the immune system to tolerate peanuts without causing allergic reactions.

Early research at Alfred Health and Monash University has developed this unique treatment, requiring a monthly dose rather than a daily dose required by current treatments.

These trials are a step forward in bringing cutting-edge healthcare to the more than 5 million Australians living with food allergies.

Aravax has received approval from the U.S Food and Drug Administration (FDA) and Australia’s Therapeutic Goods Administration (TGA) for Phase 2 trials in both countries. Phase 1 clinical trials were successfully completed for adults in Victoria in 2018.

Phase 2 trials, which will evaluate the treatment’s effect in children aged 4 to 17, will take place in clinics in Australia and the United States.

Health technology is one of the fastest growing sectors in Victoria, generating $3.02 billion in exports and supporting more than 30,000 jobs.

Investment into Aravax builds on the Victorian Government’s continued support of the health technology industry, which is driven by Breakthrough Victoria and the $20 million Australian Medtech Manufacturing Centre.